EMA's concept paper defines biosimilar regulation problem areas
This article was originally published in Scrip
Executive Summary
It looks as though forthcoming updates to guidelines on developing biosimilar medicines will reflect "current thinking and enhanced learning", if the European Medicines Agency's concept paper on proposed revisions are anything to go by, says Cecil Nick, a consultant for Parexel. The concept paper, put out for consultation on 3 October 2011, address issues including clinical equivalence studies requirements on immunogenicity.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.